The Roles of Telomerase in the Generation of Polyploidy during Neoplastic Cell Growth  by Christodoulidou, Agni et al.
The Roles of Telomerase in
the Generation of Polyploidy
during Neoplastic Cell Growth1,2
Agni Christodoulidou*, Christina Raftopoulou*,
Maria Chiourea*, George K. Papaioannou*,
Hirotoshi Hoshiyama†, Woodring E. Wright†,
Jerry W. Shay†,‡ and Sarantis Gagos*
*Laboratory of Genetics and Gene Therapy, Center of
Basic Research II, Biomedical Research Foundation
of the Academy of Athens, Athens, Greece; †Department
of Cell Biology, University of Texas Southwestern Medical
Center, Dallas, TX; ‡King Abdulaziz University, Center
of Excellence in Genomic Medicince Research, Jeddah,
Saudi Arabia
Abstract
Polyploidy contributes to extensive intratumor genomic heterogeneity that characterizes advanced malignancies and is
thought to limit the efficiency of current cancer therapies. It has been shown that telomere deprotection in p53-deficient
mouse embryonic fibroblasts leads to high rates of polyploidization. We now show that tumor genome evolution
through whole-genome duplication occurs in ∼15% of the karyotyped human neoplasms and correlates with disease
progression. In a panel of human cancer and transformed cell lines representing the two known types of genomic in-
stability (chromosomal and microsatellite), as well as the two known pathways of telomere maintenance in cancer (tel-
omerase activity and alternative lengthening of telomeres), telomere dysfunction–driven polyploidization occurred
independently of the mutational status of p53. Depending on the preexisting context of telomere maintenance, telome-
rase activity and its major components, human telomerase reverse transcriptase (hTERT) and human telomerase RNA
component (hTERC), exert both reverse transcriptase–related (canonical) and noncanonical functions to affect tumor
genome evolution through suppression or induction of polyploidization. These new findings provide a more complete
mechanistic understanding of cancer progression that may, in the future, lead to novel therapeutic interventions.
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Introduction
Chromosomal instability in neoplasia (CIN) is the most common
form of genomic instability occurring in virtually all types and stages
of cancer [1–3]. In contrast to microsatellite instability in neoplasia
(MIN) that causes DNA mismatch repair errors [1], CIN massively
affects the integrity and dosage of chromosomes through structural
rearrangements and numerical aberrations such as aneuploidy and
polyploidization [2]. Although most tumors are monoclonal in origin,
chromosomal imbalances emerge in the early steps of carcinogenesis
[4], are often distributed randomly among cancer cells [5], and may
activate oncogenic pathways [6,7]. Such extensive intratumor genomic
heterogeneity provides the grounds for a process of selection and adap-
tation that drives cancer cell populations into more malignant traits and
is a major concern for all current and future oncotherapeutic strategies
[8,9]. Radiotherapy and many anticancer drugs induce growth arrest
in the G2/M phase of the cell cycle that frequently leads to polyploidi-
zation [10,11]. Drug- or irradiation-induced polyploidy usually leads to
cell death by mitotic catastrophe [12]. However, it has been proposed
that polyploidization may be associated with the emergence of cancer
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stem–like cells that confer therapy resistance to anticancer agents [13].
Therefore, a better understanding of the mechanisms regulating poly-
ploidization is critical not only to decipher fundamental aspects of
carcinogenesis but also for achieving efficient therapies against ad-
vanced malignancy.
Telomeres are specialized nucleoprotein complexes that protect
the ends of eukaryotic chromosomes [14]. These highly repetitive
entities are progressively depleted after each round of DNA replica-
tion in all dividing human somatic cells [15]. The loss of telomeric
DNA is replenished by the action of the ribonucleoprotein telomerase,
or by a rarer DNA recombination pathway, termed alternative length-
ening of telomeres (ALT), that maintains telomere length in the
absence of telomerase [16]. Because most normal human somatic
tissues do not possess a constitutive means to fully maintain their
telomeres, actively dividing cells demonstrate progressive telomeric
length reductions with each cell division [17]. When a single, or a
few, critically short telomeres occur, DNA damage responses are acti-
vated and cells undergo a growth arrest [15,18,19].
In normal cells, senescence or apoptosis acts as a biologic barrier
to prevent neoplastic transformation [20–22]. To bypass these con-
straints, human malignancies sustain continuous growth by either
activating telomerase [23,24] or engaging ALT [25,26].
Extreme telomere shortening is known to provoke terminal chro-
mosome fusions and structural chromosome aberrations [18]. Such
changes appear to occur early in neoplasia and coincide with chro-
mosomal instability [2,27]. Telomere-driven genomic instability is
characterized by frequent chromosomal break-fusion-bridge (B/F/B)
cycles [28] that generate various types of oncogenic structural rearrange-
ments and may affect numerical chromosomal constitution through
whole chromosome losses because of anaphase lags [28–30].
Numerical chromosomal instability per se is also related to tumor-
igenesis: Cells and animals with reduced levels of centromere-associated
protein-E (CENP-E) frequently become aneuploid because of random
missegregation of one or a few chromosomes in the absence of DNA
damage [31]. Depletion of CENP-E contributes to cellular transfor-
mation and causes a modest increase in spontaneous tumor formation
[31]. In addition, patients with mosaic variegated aneuploidy syndrome,
caused by mutations in the mitotic spindle checkpoint gene BUB1B,
develop malignancies such as rhabdomyosarcomas, Wilms tumors, and
leukemias [32]. However, induction of aneuploidy can also be an effec-
tive inhibitor of tumorigenesis [31]. While low levels of aneuploidy
may provide the grounds for progressive oncogenic transformation,
extremely accelerated rates of CIN may dramatically affect cancer cell
homeostasis and may initially be a powerful anticancer protection
mechanism [9,31].
A mechanistic link between telomere dysfunction, defective cell cycle
checkpoints, and tetraploidization, through whole-genome endore-
duplication, has recently been reported [33]. This model fits well with
the hypothesis that polyploidy can lead to extended aneuploidy and
heteroploidy in human solid tumors [34]. A combination of the two
models predicts that, early in oncogenesis, telomere dysfunction and
abrogated DNA damage responses allow the generation of somatic
polyploid clones that can become highly aneuploid through subsequent
divisions influenced by B/F/B-induced anaphase lags [8,28]. Tumor
cell evolution will then be driven by selective pressure during contin-
uous growth that leads to amplification of oncogenes and depletion of
tumor suppressor pathways [35].
From earlier studies on the clonal evolution of tumor cell popu-
lations, we proposed that polyploidization through genome redupli-
cation could reflect a process of genome evolution that is observed
in vivo in tumor cells [36,37]. Genome reduplication occurs also
in culture of immortalized human cancer cell lines and may be re-
lated to telomere dysfunction [38,39]. We now provide evidence that
polyploidization is a common cause of neoplastic genome evolution
in humans and correlates with progression of disease. We examined
the effects of telomerase in a panel of cell lines representing the two
known contexts of genomic instability in neoplasia, CIN and MIN, as
well as the two known pathways of telomere maintenance (telomerase
and ALT). We show that “telomere dysfunction–driven polyploidization”
is a universal source of tumor evolution that occurs continuously
during neoplastic cell growth in culture and can be triggered to be
massive during telomeric crisis at the interface between different
pathways of telomere maintenance. Interestingly, telomerase activity
and the ectopic expression of its major components human telo-
merase reverse transcriptase (hTERT) or human telomerase RNA
component (hTERC) exert both reverse transcriptase–related (canoni-
cal) and noncanonical functions to suppress or induce polyploidy.
These new findings provide a more complete mechanistic understand-
ing of cancer progression that may, in the future, lead to novel thera-
peutic interventions.
Materials and Methods
Data Mining from Cytogenetic Databases
On the basis of the International System for Human Cytogenetic
Nomenclature 2009 [40], we examined neoplastic karyotypes that are
included in two open access databases: 1) the National Cancer Institute,
Mitelman Database of Chromosome Aberrations and Gene Fusions in
Cancer (http://cgap.nci.nih.gov/Chromosomes/Mitelman) [41] and 2)
the National Center for Biotechnology Information (NCBI) Spectral
Karyotyping (SKY)/Multiplex Fluorescence In Situ Hybridization
(M-FISH) and Comparative Genomic Hybridization database (http://
www.ncbi.nlm.nih.gov/projects/sky) [42]. For the first database, we
used the EXCEL software (Microsoft) to calculate frequencies of
neoplastic genomes with documented evidence of polyploidization.
Genome duplication or multiplication in tumor evolution has been
directly recorded in a proportion of human neoplasms included in
the Mitelman Database using the International System for Human
Cytogenetic Nomenclature symbols idemx2, idemx3, etc., that sym-
bolize whole-genome duplication (WGD), whole-genome triplication,
etc. Taking into consideration the high rates of chromosome losses
occurring in neoplastic genomes [34], we included cases with recorded
numerical chromosome alterations ranging from near-triploidy (58–
80 chromosomes) to extreme polyploidy. For the NCBI SKY/M-FISH
and Comparative Genomic Hybridization database, as polyploidy
deriving karyotypes, we considered those presenting an over diploid
chromosome number (50–200 chromosomes) displaying in addition at
least two individual pairs of identical structurally altered (marker) chro-
mosomes or four individual homologous chromosomes in tetrasomy.
Cell Lines and Culture Conditions
HCT-116, HCT-116 p53−/− [43], and T-24 cells were provided
by Drs C. Dimas and T. Vlahou (Biomedical Research Foundation of
the Academy of Athens, Athens, Greece). Lisa-2, Ls-2, and HIO-118
were kindly provided by Dr D. Broccoli (Fox Chase Cancer Center,
Philadelphia, PA). A-549 cell line was a gift from Dr G. V. Gorgoulis
Neoplasia Vol. 15, No. 2, 2013 Polyploidy and Telomerase in Neoplasia Christodoulidou et al. 157
(School of Medicine, University of Athens, Athens, Greece). T-47D
cell line was a gift from Dr A. Klinakis (Biomedical Research Foun-
dation of the Academy of Athens). HeLa and breast cancer MCF-7
cells were a gift from Dr I. Irminger-Finger (Geneva Medical School,
Geneva, Switzerland). The osteosarcoma cell line U2-OS was provided
by Dr E. Gonos (Greek National Institute for Research, Athens,
Greece). The colon cancer SW-480 and the osteosarcoma Saos2 cell
lines were obtained from American Type Culture Collection (ATCC;
Wesel, Germany). The ALT cell lines GM-847 and VA-13 were pro-
vided by Dr A. Londoño-Vallejo (Institute Curie, Paris, France). In ad-
dition, we used a VA-13 derivative cell line that stably expresses hTERC
and hTERT and has reconstituted telomerase activity (VA-13TA)—
described in Ford et al. [44]—and HCT-15 with four different deriv-
ative cell lines as described in Bechter et al. [45]. The HCT-15 cells
express a dominant mutant version cDNA resulting in inhibition of
wild-type endogenous hTERT. The sublines (SL1 and SL2) were
Telomeric Repeat Amplification Protocol (TRAP; telomerase activity)–
positive HCT-15 parental cells, and SL3 to SL8 were TRAP-negative
sublines representing subsequent population doublings (PDs) of cells
(PD27–PD107) after stable expression of the dominant negative cDNA
against hTERT [45]. We also used a derivative subline of SL3 to
SL8, in which telomerase activity was spontaneously restored after
PD180 (SL10) [45]. To produce the G7-pssi10189–Krüppel-associated
box (KRAB) cell lines, we infected ALT VA-13 cells with tetracycline-
on–inducible (TRE) hTERT with puromycin-resistant M2 vector
(rtTAsM2), which expresses a reverse tetracycline activator to switch
on hTERT transcription and the KRAB transcriptional silencer with
G418 resistance, which binds tetracycline-on and represses basal
hTERT transcription. The VA-13InTAa, b, and c were G7-pssi10189–
KRAB derivative polyclonal populations that were independently trans-
duced with an additional lentiviral vector expressing wild-type hTERC
(pssi6499) with blasticidin selection marker and red fluorescent pro-
tein for detection. The U2-OS and Saos2 cells were either transduced
with green fluorescent protein (GFP) lentivirus pLOX-GFP-iresTK
or hTERT lentivirus pLOX-GFP-TERT-iresTK (kindly donated by
Dr D. Trono). All cell cultures were grown at 37°C and 5% CO2 in
Dulbecco’smodified Eagle’smedium (Gibco,Grand Island,NY) supple-
mented with 10% FBS (Gibco), 25 units/ml penicillin (Sigma, St Louis,
MO), and 25 pg/ml streptomycin (Invitrogen, Grand Island, NY).
Cytogenetics
Logarithmically growing cell cultures were exposed to colcemid
(0.1 μg/ml) (Gibco) for 1 to 3 hours, at 37°C in 5% CO2. Cells were
harvested by trypsinization (Gibco), suspended in medium, and spun
down (10 min, 1000 rpm). Supernatant was removed completely and
5 ml of 0.075M KCl (Sigma) at room temperature was added drop by
drop. The cells were incubated for 20 minutes at room temperature,
and then 1 ml of fixative [3× methanol (Applichem GmbH, Darmstadt,
Germany)/1× CH3COOH (Merck, Darmstadt, Germany)] was added.
Cells were spun down (10 minutes at 1000 rpm), supernatant was
removed, fixative was added, and the cells were recentrifuged for
10 minutes at 1000 rpm. Finally, cells were dropped onto wet micro-
scope slides and left to air-dry. For the quantitation of chromosome
number per metaphase, we combined inverted 4′,6′-diamidino-2-
phenylindole (DAPI) staining, G-Banding, and molecular karyotyping
byM-FISH (MetaSystemsGmbH,Altlussheim,Germany).G-Banding
was performed after treatment with 0.25% trypsin (Gibco) and Giemsa
(Carl Roth GmbH, Karlsruhe, Germany) staining. Multicolor FISH
was performed according to the manufacturer’s protocols (MetaSystems
GmbH). For inverted DAPI banding, slides were counterstained and
mounted with 0.1 μg/ml DAPI in VECTASHIELD antifade medium
(Vector Laboratories, Burlingame, CA). Cytogenetic analyses were per-
formed using a ×63 magnification lens with a charge-coupled device
(CCD) camera on a fluorescent Axio Imager Z1 Zeiss microscope and
the MetaSystems Ikaros or Isis software.
Fluorescence In Situ Hybridization
For interphase or metaphase FISH, we used satellite probes specific
for the centromeres of chromosomes 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 16,
17, 18, 20, and X. Probes were purchased from Vysis (Abbott Park, IL)
and Cytocell (Cambridge, United Kingdom). In brief, our protocol was
based on pepsin (Invitrogen) pretreatment, formamide (Applichem) or
NaOH (Sigma) target denaturation, overnight hybridization, and high-
stringency post-hybridization washes. Telomeric peptide nucleic acid
(PNA) FISH was performed according to the manufacturer’s instruc-
tions (Dako Cytomation, Glostrup, Denmark). Briefly slides were
incubated at 3.7% formaldehyde (Carlo Erba Reagenti SpA, Milano,
Italy), washed with 1× TBS (Dako Cytomation), immersed in pretreat-
ment solution (Dako Cytomation), and dehydrated with cold ethanol
series (VWR, Radnor, PA). Probe and target DNA were denatured at
80°C for 5 minutes and then slides were incubated for 1 hour at room
temperature in the dark. For multicolor FISH, we used the 24XCyte
Kit from MetaSystems GmbH. Staining was performed according to
the manufacturer’s instructions. All FISH preparations were mounted
and counterstained with VECTASHIELD antifade medium containing
0.1 μg/ml DAPI (Vector). Digital images were captured and enhanced
in a MetaSystems workstation as described above.
Telomeric Repeat Amplification Protocol
Telomerase activity of cell lysates was analyzed by the TRAP assay
with a TRAPeze Telomerase Detection Kit (Chemicon, Billerica, MA)
according to the manufacturer’s instructions. Approximately 106 cells
were harvested and lysed in 200 μl of 1× CHAPS lysis buffer [10 mM
Tris-HCl (pH 7.5), 1 mM EGTA, 1 mMMgCl2, 0.5% CHAPS, 10%
glycerol, 5 mM β-mercaptoethanol, and 0.1 mM benzamidine] on ice
for 30minutes. Polymerase chain reaction (PCR) products were electro-
phoresed in a 10% 19:1 acrylamide gel (Sigma) in 0.5× Tris/Borate/
EDTA buffer (Sigma) using the Mini-PROTEAN II Gel System (Bio-
Rad, Hercules, CA). Gels were stained either with 1:10,000 SYBRGreen
(Sigma) in 0.5× Tris/Borate/EDTA buffer for 15 minutes at room tem-
perature and then exposed to UV light and visualized in a Kodak image
acquisition station with Dolphin software or by radioisotopic detection
using P32-labeled deoxycytidine triphosphates (dCTPs; Amersham,
Uppsala, Sweden). Radiolabeled gels were dried in a Heto Lyo Pro3000
Dryer and visualized with a Typhoon 9200 Imager.
Telomerase Silencing
The telomerase-positive SW-480 cell line was transiently transfected
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions, with ds small interfering RNA (siRNA) targeted against
hTERT (Ambion, Grand Island, NY; sense, 5′-GGCUCUUUUUCU
ACCGGAAtt-3′; antisense, 5′-UUCCGGUAGAAAAAGAGCCtg-3′).
Cells were seeded in T25 flasks and/or six-well plates at appropriate
cell densities 1 day before transfection to be subconfluent the first day
of the experiment. The siRNA/Lipofectamine ratio was 20 pmol/μl.
SW-480 cells were subjected to sequential transfections with siRNA,
separated by 72- to 96-hour intervals. Cells were maintained in culture
for 10, 30, or 60 days before harvest and collection of cell pellet. In
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addition, the SW-480 cell line was transduced with LentiLox 3.7
(pLL3.7), which contained a short hairpin RNA (shRNA) designed
to silence hTERT. The shRNA for hTERT was synthesized at the
FORTH Institute (Crete, Greece) and had the following sequence:
sense, 5′-GATCCCCTTTCATCAGCAAGTTTGGATTCAAGA-
GATCCAAACTTGCTGATGAAATTTTTA-3′; antisense, 3′-GGG-
AAAGTAGTCGTTCAAA-CCC TAAGTTCTCTAGGTTTGAAC-
GACTACTTTAAAAA-TTCGA-5′. Enrichment of transduced cells
was performed with the aid of an ARIA cell sorter (Beckman Coulter,
Nyon, Switzerland) using GFP as a selection marker. After selection,
more than 90% of the cells were GFP positive. We also exposed the
SW-480 cell line to the telomerase inhibitor N ,N -1′,3′-phenylenebis-
[2′,3′-dihydroxy-benzamide] (MST312) [46]. Briefly, 3 × 10−6 M of
MST312 (kindly donated by Dr H. Seimiya) diluted in DMSO
(Sigma) was added to the culture medium of subconfluent T25 flasks
for 5 and 10 days. Medium was changed every 2 days. Similar pro-
cedure for telomerase inhibition through MST312 was followed for
the telomerase-positive VA-13TA, A-549, and T-47D cell lines.
Reverse Transcription–PCR
Semiquantitative reverse transcription (RT)–PCR was performed
as follows: 2 μg of total RNA was isolated from each cell line and
incubated at 70°C for 5 minutes with 0.5 μg of oligo T17 (custom-
made from the FORTH Institute). RT-PCR was followed with the
mix containing 2 μl of 10× RT buffer (Promega, Madison, WI),
2.4 μl of 25 mM MgCl2 (Promega), 1 μl of 5 mM deoxynucleotide
triphosphates (dNTPs; Promega), and 0.5 μl of reverse transcriptase
(Promega) in H2O to a final volume of 20 μl. The transcription reaction
was performed at 25°C for 5 minutes, 42°C for 1 hour, 70°C for
15 minutes, and then cooled down to 4°C. Amplification of the hTERT
in 5 μl of cDNA was performed with 5 μl (20 μM) of each of the
following primers: 5′-AGGCTGCAGAGTGCAGAGCAGCGTGG-
AGAGG-3′ and 5′-GCCTGAGCTGTACTTTGTACTTTGTCAA-
3′; for hTERC, the primers were 5′-TTTCCCTAACCCTAA-3′ and
5′-AATCCGTCGAGCAGAGTT-3′, and for GAPDH, the primers
were 5′-CTTACTCCTTGGAGGCCATG-3′ and 5′-TTAGCA-
CCCCTGGCCAAGG-3′ (custom-made from the FORTH Institute).
The PCR products were analyzed by electrophoresis in 8%nondenaturing
polyacrylamide gel and stained with SYBR Green (1:10,000); images were
acquired at a Kodak image acquisition station equipped with Dolphin soft-
ware, and bands were quantified using ImageQuant (MD/APS software).
Immunocytochemistry and Immuno-FISH
In situ dual-color immunofluorescent cytochemistry (IF) was per-
formed on cells grown on coverslips. Cells were fixed in ice-cold
methanol for 10 minutes at −20°C, permeabilized with 0.2% Triton
Figure 1. Frequencies of polyploidization in Mitelman Catalog of Chromosome Abnormalities in Cancer: Data mining in a total of 59,772
karyotyped samples of human neoplasms included in Mitelman Database at the time of our analysis reveals that polyploidization
through WGD occurs in virtually all types of human neoplasia, affecting about 15% of all cases. The percentages of WGD between
different histopathologic entities varied between 1% and 15% (A). In several types of solid tumors, the frequencies of recorded
WGD were found accelerated in cases representing disease progress or higher grades of malignancy: Note a three-fold to four-fold
increase in the rates of WGD when adenomas are compared to adenocarcinomas, or squamous cell carcinomas, as well as between
benign epithelial neoplasms or carcinomas in situ and malignant epithelial neoplasms. In melanocytic tumors, identification of WGD
might be an indication of malignancy because benign dysplastic nevi do not exert WGD (B). Only 5% to 6% of total adipose tumors
display evidence of WGD; however, the presence of WGD is strongly associated to disease progression from the benign lipomas and
well-differentiated myxoid liposarcomas to the more malignant dedifferentiated or pleiomorphic liposarcomas (C).
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for 12 minutes at 4°C, and blocked with 1% BSA for 1 hour at room
temperature. Coverslips were incubated with appropriate antibodies
in 1% BSA overnight at 4°C in humidity. For antibody detection, we
used Alexa Fluor 488 and Alexa Fluor 568 (Molecular Probes, Grand
Island, NY) and Cyanine 5 (BD Biosciences, Franklin Lakes, NJ)
diluted 1:500 in 1% BSA for 1 hour at room temperature in humid-
ity. For telomere-specific immuno-FISH, coverslips were post-fixed
with ice-cold methanol for 10 minutes at −20°C and washed with
phosphate-buffered saline, and then PNA FISH was applied as de-
scribed above. Primary antibodies used for IF were specific for hTERT
(Epitomics, Burlingame, CA), telomeric repeat factor 2 (TRF2; Santa
Cruz Biotechnology, Santa Cruz, CA), γ-H2AX (clone JBW301;
Millipore, Billerica, MA), γ-tubulin (Abcam, Cambridge, MA), and
α-tubulin (Sigma; 1:500). Promyelocytic leukemia (PML; Santa Cruz
Biotechnology), home-made 53BP1 and ataxia telangiectasia and Rad3
related (ATR) interacting protein (ATRIP; kindly donated by Dr T.
Halazonetis), and replication protein A1 (RPA1; Calbiochem, Billerica,
MA) antibodies (1:50–1:100) were also used. Coverslips were dehy-
drated and mounted onto microscope slides with VECTASHIELD
containing DAPI as above. Digital images were captured in a Meta-
Systems workstation as described above.
Statistical Analysis
One-way analysis of variance, paired t test, and chi-square analyses
were performed using the MINITAB software. Error bars represent
SEM. In WGD graphs, error bars indicate SEM between two or more
repetitive experiments.
Results
WGD Occurs in All Histopathologic Types of Human
Neoplasia and Correlates with Disease Progression
and Malignancy
Extensive cytogenetic studies have shown that a significant number
of cancer genomes evolve with polyploidy and widespread aneuploidy
[10,47–49]. Such altered genomes exert hyperdiploid chromosomal
contents with modal chromosome numbers varying from near-triploidy
(58–80 chromosomes) to hyper-polyploidy (i.e., 200–400 chromo-
somes) [40]. To identify if polyploidization is a common process of
tumor genome evolution and to estimate the frequencies, we applied
cytogenetic criteria to examine neoplastic karyotypes of two National
Cancer Institute databases [41,42]. On the basis of a broad and con-
servative analysis, we found that ∼15% of the total karyotyped neo-
plasias are evolutionary products of polyploidization through WGD
(Figure 1A). In several tumor types, high frequencies of polyploidiza-
tion were associated with disease progress and malignancy (Figure 1, B
and C ). Nevertheless, the proportions of recorded WGD may be sub-
stantially underestimated because of technical issues. To test this pos-
sibility, we examined the frequency of WGD in 290 human cancer
specimens and tumor cell lines included in the public NCBI SKY/
Figure 2. Mitotic and interphase polyploidies in a panel of human cancer and immortalized cell lines: WGD in cytogenetic preparations
of SW-480 cells stained by DAPI (blue) and centromere-specific probes for chromosomes 3 (red, Texas Red) and 9 (green, fluorescein
isothiocyanate) (A). Mitotic presence of diplochromosomes reveals endoreduplication-driven WGD in SW-480 cells lentivirally transduced
with shRNA against hTERT (B). Interphase WGD in U2-OS nuclei labeled with inverted DAPI (gray) and centromeric probes specific for
human centromeres 3 (red, Texas Red), 7 (green, fluorescein isothiocyanate), and 18 (blue, spectrum aqua) (630×) (C). Comparison of the
rates of mitotic and interphase WGDs in 14 continuous human cell lines: Telomerase activity is indicated as (+) or (−) by TRAP. Status of
p53 is indicated as wild type (WT) or mutated (M) (Table W1). HCT-15 and HCT-116 cell lines display MIN [45,53]. The remaining 12 cell
lines can be categorized as CIN. The ALT cell lines that are characterized by extreme rates of telomere dysfunction display a significantly
higher propensity for both interphase and mitotic WGDs (P < .0001 by analysis of variance) (D).
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M-FISH Cancer Chromosome Database (http://www.ncbi.nlm.nih.
gov/projects/sky) [42]. Approximately 60% of the molecular karyo-
types included in the NCBI database, at the time of our analysis, could
be considered by-products ofWGD. Therefore, independently of tissue
of origin, grade, or histopathologic type, a considerable proportion of
karyotyped human cancer genomes have evolved toward malignancy
through a process of polyploidization.
Experimentally Immortalized and Cancer Human Cell Lines
Using the ALT Display High Rates of WGD
Compared to telomerase-positive examples, ALT tumors and ex-
perimentally immortalized cell lines demonstrate increased rates of
endogenous telomere dysfunction and structural chromosome instabil-
ity [50–52]. To investigate differences in the rates of WGD between
cells using the ALT pathway and cells that require telomerase for con-
tinuous growth, we combined dual-color centromere-specific FISH
with classic and molecular karyotyping (M-FISH/SKY) in seven
telomerase-positive and seven ALT human cell lines (Figure 2). These
duplicate data sets confirm each other with independent cytogenetic
methods, providing, in parallel, higher throughput of information for
percentages of polyploidy in the whole-cell population of a given
harvest. Interphase and mitotic nuclei of the ALT cell lines of our com-
parative panel showed a significantly higher propensity for WGD
(Figure 2D), linking polyploidization to increased rates of endogenous
ALT telomere dysfunction. Consistent with previous results [53], p53
deficiency in the MIN HCT-116 cell line increased two-fold the rates
of endogenous mitotic and interphase WGDs in the absence of telo-
mere dysfunction, leading to stochastic selection of tetraploid subclones
(Figure W1). However, further analysis did not reveal a correlation
between WGD and mutations in p53 (Figure 2 and Table W1). These
observations support the view that, independent of the status of p53,
Figure 3. Inducible telomere dysfunction in CIN and MIN cell lines is associated with increased frequencies of WGD: Depletion of hTERT
by serial transient siRNA transfections, lentiviral transduction with an shRNA against hTERT, or exposure to the telomerase inhibitor
MST312 in the CIN SW-480 cells is associated with increased telomere dysfunction and significantly elevated levels of mitotic and
interphase WGDs (A). Telomerase inhibition through MST312 for 10 days results to insignificant increase in end-to-end fusions but still
leads to significant induction of WGD in two additional CIN cell lines with extremely low rates of endogenous polyploidization (A-549 and
T47D) (B). Robust hTERT knockdown in different sublines of the MIN HCT-15 colon adenocarcinoma cell line, representing consequent
PDs after retroviral introduction of an antimorph against hTERT. After PD180, telomerase activity is spontaneously restored (SL10) [45].
In this setting, telomerase knockdown leads to increase in telomere dysfunction and WGD, whereas restoration of telomerase activity
suppresses WGD (C). Statistics by paired t test or chi-square test.
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both telomerase-positive examples and ALT cell lines exert a proportion
of mitotic or interphase WGD that is significantly more pronounced in
the ALT cells.
Telomerase Depletion/Inhibition in CIN and MIN Tumor
Cell Lines Is Related to Increased Rates of Telomere
Dysfunction and Polyploidy
Mouse embryonic fibroblasts growing in the absence of telome-
rase activity show increased propensity to undergo WGD through
endoreduplication and the formation of diplochromosomes [27].
Furthermore, knockdown of telomerase in the near-diploid MIN
human colon cancer cell line HCT-116 is associated with increased
rates of tetraploidization [53]. To confirm these findings in both
MIN and CIN human cell lines, we tested depletion/inhibition of
telomerase activity in another MIN cell line (HCT-15) and in the
CIN cancer cell lines SW-480, T-47D, and A-549 (all express
telomerase; Figure 3). Telomerase activity was suppressed in the SW-
480 cells by transient hTERT siRNA transfection [50] and stable shRNA
hTERT lentiviral transduction or treated with the telomerase in-
hibitor MST312 [46] (Figure 3A and Figure W2). The T47-D and
A-549 cells were treated with MST312 (Figure 3B). We also examined
multiple subclones of the stably transfected HCT-15 (MIN) cell line
expressing a dominant negative cDNA against hTERT [45]. The
HCT-15 (SL4–SL8) cells efficiently expressed the introduced domi-
nant negative gene for more than 100 PDs and engaged ALT-like telo-
mere elongation [45]. However, after 120 PDs, they spontaneously
regained telomerase activity and the adverse effects of telomere dys-
function were rescued [45]. Telomere dysfunction in HCT-15
(SL4–SL8) cells was accompanied by increased rates of interphase
and mitotic tetraploid nuclei. In contrast, spontaneous reconstitu-
tion of telomerase activity in the same cells suppressed the increased
tendency toward tetraploidy (Figure 3C ). These findings suggest
that continuous growth after telomerase inhibition in telomerase-
positive MIN and CIN human cancer cell lines is accompanied by
telomere dysfunction and the spontaneous emergence of polyploidy.
Stable Reconstitution of Telomerase Activity in ALT Cells
Correlates with a High Prevalence of Polyploid Cells
but Low Rates of Random Polyploidization
In view of the above results, we reasoned that reconstitution of
telomerase activity in ALT cells that is known to repress endogenous
telomere dysfunction [44] will also suppress the increased rates
Figure 4. Constitutive telomerase activity in ALT cells reduces telomere dysfunction but is related to high prevalence of polyploidy: Long-
term stable reconstitution of telomerase activity in the VA-13TA cell line through exogenous introduction of hTERC and hTERT (indicated
by TRAP) reduces significantly endogenous telomere dysfunction, as indicated by the rates of chromosome end-to-end fusions and TIFs,
and suppresses the rates of WGD (A). Prolonged exposure to telomerase activity in VA-13TA is accompanied by high prevalence of poly-
ploid nuclei composed from 117 to 120 chromosomes (98%). Multicolor FISH indicates that the representative VA-13TA karyotype
contains duplicated copies of several structurally altered chromosomes of the parental ALT VA-13 cells (arrows) (630×) (B). Statistics
by paired t test or chi-square test.
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of endogenous WGD. To test this, we used the ALT VA-13 cells (T-
antigen immortalized human embryonic WI38 fibroblasts) that were
stably transfected with hTERT and hTERC and expressed telomerase
activity for more than 200 PDs (VA-13TA) [44] (Figure 4A). Surpris-
ingly, the VA-13TA cells showed an extremely high prevalence of
polyploid nuclei (98% of total cells) with modal chromosome num-
bers ranging between 117 and 120 chromosomes (Figure 4B). The kar-
yotypic characteristics of the near-pentaploid VA-13TA cells indicated
that they were by-products of near-triploid progenitor VA-13 cells that
had undergone one round of WGD. Nevertheless, the near-pentaploid
VA-13TA exhibited only low rates of random mitotic and interphase
WGDs similar to those of telomerase-positive cell lines (2–4%;
Figures 2D and 4A). Such rare mitotic nuclei had undergone an addi-
tional round of WGD and displayed a hyperoctaploid genomic content
of 220 to 240 chromosomes. Expectedly, the low frequencies of hyper-
octaploid nuclei in VA-13TA cell line were significantly increased upon
exposure of the cells to the telomerase inhibitor MST312 (Figure W4).
Thus, in the ALT context, long-term reconstitution of telomerase ac-
tivity reduces the rates of telomere dysfunction and WGD but can be
related to high prevalence of polyploidization. This suggests that, in
immortalized ALT cells, the initial steps of the simultaneous action
of both known telomere maintenance pathways in mammals may be
accompanied by massive telomere dysfunction.
Inducible Telomerase Activity in ALT Cells Elicits
Telomere Dysfunction and Polyploidization
To further investigate the unexpected predominance of polyploid
nuclei in VA-13TA cells, we generated three stable cell line deriva-
tives of the ALT VA-13 cells (InTAa, InTAb, and InTAc; Table W2).
These multiclonal cell lines constitutively express hTERC and stably
maintain a tetracycline-inducible hTERT cassette, capable of fully
activating telomerase reverse transcriptase activity as indicated by
TRAP assays (Figures 5A and W3B). In InTAa, b, and c cells, con-
stitutive expression of hTERC was associated with increased rates of
telomere dysfunction and polyploidization, as compared to parental
VA-13, and cells were transduced with empty vectors (Figure 5, B and
C ). Consistent with our hypothesis, inducible reconstitution of telo-
merase activity accelerated preexisting rates of telomere dysfunction,
Figure 5. Inducible reconstitution of telomerase activity in ALT cells increases telomere dysfunction and polyploidy through WGD: TRAP
assay shows inducible telomerase activity in the VA-13 derivative multiclonal cell lines InTAa and InTAb, after 5 days in doxycycline (A).
Reconstitution of telomerase activity in InTAb cells increases frequencies of chromosome end-to-end fusions (arrows) and WGD
(inverted DAPI, 630×) (B). Constitutive expression of hTERC in the three InTA (a, b, and c) cell lines is related to a significant increase
in telomere dysfunction–driven chromosome terminal fusions as compared to parental WT cells and the TA cell line that stably expresses
telomerase activity. The rates of telomere dysfunction after 5 days in doxycycline and activation of the telomerase holoenzyme are
highly accelerated. Elevated frequencies of WGD in mitotic and interphase nuclei of different VA-13 cell lines correspond to the rates of
telomere dysfunction (C). Statistics by paired t test or chi-square test.
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Figure 6. Nuclear association of telomeric binding TRF2 with DDR proteins and of hTERT with telomeric repeats in VA-13 cells. Examples
of nuclear co-localization of TRF2-specific antibodies, with the DDR proteins RPA1, ATRIP, PML, and γ-H2AX, by immunofluorescence, in
parental ALT VA-13 (WT), in InTAb (constitutive expression of hTERC), in InTAb + doxycycline cells (inducible expression of hTERT and
telomerase activity after 5 days of doxycycline in culture), and in VA-13TA cells that constitutively express both holoenzyme components
and display telomerase activity for more than 200 PDs (630×). The graph depicts frequencies of spatial interaction of TRF2 with ATRIP,
PML, 53BP1, RPA1, and γ-H2AX by dual-color IF in 100 nuclei/cell line. Constitutive overexpression of hTERC in the three independent
InTA (a, b, and c) cell lines is associated with significantly reduced co-localization rates of TRF2 with PML (P = .001, P = .002, and P =
.001) and ATRIP (P= .007, P= .003, and P= .002), whereas rates of classic TIFs (co-localization of TRF2 with γ-H2AX) remain unaffected.
Doxycycline-induced reconstitution of telomerase activity in these cell lines restored levels of co-localization between TRF2 and PML (P=
.012, P= .000, and P= .012, respectively) or ATRIP (P= .007, P = .001, and P = .001, respectively), increasing in parallel frequencies of
classic TIFs and the rates of spatial association of TRF2 with 53BP1 (P= .045, P= .018, and P= .034, respectively) and RPA1 (P< .0001,
P= .001, and P< .0001). Inducible expression of hTERT alone, in the InTERT cells, did not exert any effects in spatial association of TRF2
with DDR components (ATRIP, P= .192; PML, P= .060; 53BP1, P= .139; RPA1, P= .786; γ-H2AX, P= .123) (A). Immuno-FISH depicts
nuclear localization of an antibody specific for hTERT and TTAGGG telomeric repeats (630×). Compared to the stable +hTERC+hTERT TA
cells, the rates of spatial association of telomerase with the telomeres are significantly elevated after 5 days of the interphase between the
sole action of ALT and the introduction of telomerase activity (InTAc + doxycycline, P= .529; InTAa and InTAb, P< .0001) (B) (all statistics
by paired t test).
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as verified in mitotic cells by frequent end-to-end chromosome fusions,
and in interphase nuclei by immunocytochemical co-localization of
the telomere-specific shelterin component TRF2 and the DNA
damage response (DDR) proteins γ-H2AX, PML, 53BP1, RPA1,
and ATRIP (Figure 6A). As expected, immediate increase in telomere
dysfunction was directly accompanied by high rates of mitotic and inter-
phase polyploidizations (Figure 5C ). Polyploid cells in neoplasia can
form by several mechanisms including cell fusion, cytokinesis failure,
or WGD due to an abortive cell cycle (endomitosis) [10]. To define
the type of polyploidization process that is activated upon ectopic expres-
sion of TERC and TERT in ALT cells, we applied immunofluorescence
assays using antibodies specific for α- and γ-tubulins and DAPI staining.
This allows localization and enumeration of centrosomes per cell, as
well as the identification of binucleated or multinucleated cells in a pop-
ulation [10,54]. The frequencies of amplified (more than two
centrosome foci per cell) and of clustered amplified centrosomes
were significantly increased upon induction of telomerase activity in
VA-13InTAa, b, and c cells (Figure W5, A and B). However, the
changes in the percentages of binucleated or multinucleated cells and
of cells with scattered amplified centromeres were insignificant
(Figure W5C). Therefore, most of the observed telomere dysfunction–
driven polyploidy resulted from WGD through endomitosis and not
due to generalized cytokinesis failure that generates multinucleated cells
with scattered centrosomes [10]. These results reveal that the introduc-
tion of telomerase activity in cells using the ALT pathway is triggering
immense telomere dysfunction responses that are capable of conferring
further tumor evolution through whole-genome endoreduplication.
Hence, telomerase activity may facilitate induction of polyploidy in
certain contexts.
Ectopic Expression of hTERC and Reconstitution of
Telomerase Activity Antagonize ALT Introducing
Telomere Dysfunction and Polyploidization
To examine the effects of ectopic expression of hTERC, and both
hTERC and hTERT, in telomere dysfunction–driven polyploidization
in the ALT pathway, we generated an additional VA-13 derivative
cell line that conditionally expresses hTERT but does not display telo-
merase activity due to endogenous absence of hTERC (InTERT;
Figure W3) [44]. We then examined spatial association of the DDR
elements γ-H2AX, PML, 53BP1, RPA1, and ATRIP with TRF2
in our panel of VA-13 derivative cell lines (Figure 6A). Suppression
of the ALT pathway has been associated with diminished spatial inter-
action of shelterin components and single-strand DNA binding DDR
proteins such as RPA1 with the ALT-associated promyelocytic leuke-
mia body (APB) bodies [55–59]. Our results indicate that polyploidy-
inducing constitutive overexpression of hTERC, in ALT cells that lack
hTERC RNA, is associated with significantly reduced rates of telomeric
localization of PML, RPA1, and ATRIP but substantially increased
rates of γ-H2AX and 53BP1, as compared to parental and control
VA-13 cells. Reconstitution of telomerase activity restored suppression
Figure 7. Ectopic expression of hTERT in the absence of telomerase activity suppresses endogenous polyploidization in ALT cells:
Semiquantitative RT-PCR indicates inducible and stable expression of hTERT, in three ALT human cell lines (A, B). In the absence of
telomerase activity, the inducible introduction of hTERT in the VA-13 derivative InTERT cell line for 30 days did not affect telomeric
integrity, as indicated by the frequencies of terminal chromosome fusions, but reduced significantly the rates of endogenous mitotic
and interphase WGDs (C). Similarly, the lentiviral transduction of U2-OS cells with particles carrying GFP or hTERT + GFP had insignif-
icant effects on telomere functionality but significantly suppressed WGD. Suppression of WGD upon ectopic expression of hTERT was
also observed in Saos2 cells. Transduction rates for U2-OS TA(A) and U2-OS GFP reached 90% to 95%, 50% to 60% for U2-OS TA(B),
and 60% to 75% for Saos2TA and Saos2 GFP (D). Statistics by paired t test or chi-square test.
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of telomeric association of PML, RPA1, and ATRIP with TRF2, but
the rates of γ-H2AX and 53BP1 assembly at telomeres were notably
increased (Figure 6A). γ-H2AX recruits 53BP1 and both bind at
double-stranded DNA breaks [60]. Escalated telomere dysfunction
was verified by increased frequency of chromosomal end fusions (Fig-
ure 5, B and C ). To further investigate the role of telomerase activity in
triggering immediate DDR at ALT telomeres, we used immuno-FISH
to examine nuclear localization of exogenously expressed hTERT, rela-
tive to the chromosome termini. In the absence of hTERC, inducible
expression of telomerase activity resulted in diffuse nuclear fluorescence
of an hTERT-specific antibody, while spatial association with telomeres
was low. Inducible telomerase activity in VA-13InTERT cells resulted
in accumulation of hTERT in nuclear foci that appear to be Cajal
bodies [61]. Co-localization of hTERT with telomeric repeats was
substantially higher as compared to the stably transfected telomerase-
positive VA-13TA cells (Figure 6B). Overall, these results indicate
that overexpression of hTERC alone, as well as the combined action
of hTERC and hTERT, antagonizes the ALT pathway of telomere
maintenance, eliciting, respectively, constitutive or transient telomeric
DDR that triggers WGD.
A Noncanonical Function of hTERT Suppresses
Polyploidization in the ALT Pathway
The introduction of hTERT in VA-13 cells, in the absence of
hTERC, did not affect association of PML, RPA1, and ATRIP, with
TRF2 and APBs and was not related to significant increase in the
frequencies of classic telomere dysfunction–induced foci (TIFs; i.e.,
co-localized TRF2 and γ-H2AX nuclear foci; Figure 6A). InTERT, a
VA-13 derivative cell line, was grown in the presence of doxycycline
for 5 and 30 days. RT-PCR of the catalytic subunit of telomerase
showed that hTERT expression was restored and remained as such
during the duration of the experiment (Figure 7A). Semiquantitative
RT-PCR showed that the levels of inducible hTERT expression were
similar to those observed in telomerase-positive cancer cell lines such
as HeLa or SW-480 (Figure W3A). At 5 and 30 days after inducible
ectopic expression of hTERT, in the absence of hTERC and telo-
merase activity, a significant decrease in the endogenous rates of
WGD was noted in VA-13InTERT + doxycycline cells (Table W2).
Interestingly, suppression of WGD was independent of the rates of
telomere dysfunction (Figures 5C and 7C ). To rule out cell line–
specific effects, we examined the hTERC/hTERT null human ALT
osteosarcoma cell lines U2-OS and Saos2 [62], transduced either with
a GFP-expressing lentivirus or the same construct expressing hTERT
(Figure 7B). Again, ectopic expression of hTERT alone, in the absence
of telomerase activity, did not affect rates of telomere dysfunction but
was accompanied by significant suppression of endogenous WGD
(Figure 7D). Collectively, these results demonstrate that, in human
ALT cells not expressing hTERC, hTERT exerts a noncanonical telo-
merase activity–independent function, acting as a negative regulator of
spontaneous polyploidization during continuous neoplastic cell growth.
Discussion
Polyploidization through WGD occurs frequently in all types and
stages of human neoplasia and may be associated with disease progres-
sion. About 15% of the karyotyped humanmalignancies show evidence
of polyploidization. However, only 49% of∼60,000 cases of Mitelman
Catalogue (at the time of our analysis) displayed a diploid or pseudo-
diploid karyotype of 46 chromosomes, suggesting that well over 50%
of all human cancers exhibit major chromosome imbalances [41]. The
tendency of cancer cells to undergo extensive chromosome losses
[29,30,34], combined with previous technical difficulties in precise
chromosome recognition and interpretation of cytogenetic aberrations
[63], as well as insufficient karyotypic recording of WGD, may have
grossly underestimated the frequencies of polyploidization as an almost
universal process of malignant genome evolution. Indeed, in the sub-
stantially smaller but more detailed NCBI M-FISH/SKY database,
about 60% of the solid tumor cases displayed evidence of clonal evo-
lution through WGD or polyploidy. Consistent with these results, a
recent meta-analysis, of allelic copy-ratio profiles derived from single
nucleotide polymorphism (SNP) arrays from 3155 cancer samples,
showed that the frequencies of WGD varied between 25% and 50%
across tumor types, reflecting differences in disease-specific biology
and clinical progression status [64].
From the pivotal work of Barbara McClintock [65], telomere dys-
function is known to produce structural chromosomal instability
and can cause chromosome losses through B/F/B cycles and anaphase
lagging [28,66]. There are frequent reports of high rates of poly-
ploidization in tissues and cells suffering from telomere dysfunction
[27,67]. Moreover, the association of tetraploidization with dysfunc-
tional telomeres in POT1a/b and p53-deficient mouse embryonic
fibroblasts suggested a common mechanism for the induction of poly-
ploidization in the early stages of tumorigenesis, when telomere dysfunc-
tion can result from excessive telomere shortening [33]. Inhibition of
telomerase activity is currently under clinical trials as a novel method to
treat human cancers [68,69]. Our data show that ablation of telomerase
in both CIN and MIN cell lines is associated with the induction of
telomere crisis and increased tendency for polyploidy. Despite some
limited clonal structural or numerical chromosome anomalies, MIN
tumors exert a remarkable propensity to maintain diploidy [1,70].
Indeed, in the presence of functional p53, spontaneous restoration of
telomerase activity in the MIN context dropped telomere dysfunction–
drivenWGD substantially, indicating negative selection for tetraploidy.
However, in the absence of p53, several subclones of the HCT-116
cells were composed solely of near-tetraploid cells. Therefore, both
CIN and MIN telomerase-positive cell lines respond to extreme telo-
mere dysfunction through WGD. Clonal expansion of tetraploid
or polyploid cells appears to occur independently of p53 in CIN
telomerase-positive or ALT cell lines. In contrast, MIN cells may de-
pend on defective p53 to maintain polyploidy.
As predicted from previous studies [44], prolonged reconstitution
of telomerase activity in ALT cells repressed a proportion of ongoing
telomere dysfunction events. Telomerase reconstitution also suppressed
the propensity for polyploidization to rates similar to those observed
in telomerase-positive cell lines. However, compared to parental ALT
VA-13, virtually all of the telomerase-positive VA-13TA cells became
polyploid. Hence, during the process of ectopic restoration of telo-
merase activity, massive polyploidization may occur. Indeed, when
we isolated or combined the effects of hTERC and hTERT, in consti-
tutive or inducible systems, we observed that the expression of hTERC
in hTERT/hTERC-null ALT cells decreased spatial interaction of
telomeres with APB bodies. This effect suppressed recombinatorial
ALT telomere maintenance [56,58,71] and raised endogenous telo-
mere dysfunction, increasing the incidence of WGD. Interestingly,
the inducible concerted action of hTERC and hTERT, to elongate
telomeres, dramatically affected telomere integrity of the ALT cells
resulting in massive local DDR that triggered terminal chromosome
fusions and increased rates of polyploidization. These results indicate
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that the initial steps of reconstitution of telomerase activity in the ALT
pathway provoke a transient telomeric crisis that is restored upon pro-
longed action of telomerase. Thus, telomerase activity despite
antagonistic effects to the ALT machinery eventually reduces telomere
dysfunction and ongoing polyploidization. However, initial telomeric
insults can be significant enough to allow emergence and clonal expan-
sion of cells with duplicated polyploid genomic content.
The introduction of hTERT, in the presence of constitutive expres-
sion of hTERC, activated the telomerase holoenzyme to initiate telomere
maintenance but also restored spatial association of the single-stranded
DNA-binding proteins ATRIP and RPA1 with telomeres at levels sim-
ilar to the parental and mock ALT cells. Combined with the increased
rates of telomere dysfunction and WGD during constitutive expression
of hTERC, the previous observations support the hypothesis that, in
the absence of hTERT, excessive hTERC may interfere with the
machinery of ALT telomere maintenance through the suppression of
terminal DNA recombinatorial replication. Apparently, the inducible
assembly of telomerase holoenzyme occupied a proportion of ALT-
interfering hTERC, so the low frequencies of the association of
RPA1/ATRIP with single-stranded telomeric DNA were rescued. How-
ever, the simultaneous activation of both pathways of telomere mainte-
nance in ALT cells was largely ineffective because it was associated with
immediate escalation of telomere dysfunction and further increase in the
rates of WGD. Since these effects are not detrimental for continuous
growth, after a number of PDs in culture, a proportion of ALT telo-
meres will be replenished by telomerase, resulting in less frequent
DDR responses at telomeres. Thus, most of the ALT machinery will
be suppressed, and high rates of endogenous WGD will be reduced
to similar levels with those observed in several telomerase-positive cell
lines. Interestingly, hTERT, the major component of telomerase, might
be involved in a negative feedback loop, acting as a direct suppressor of
polyploidy through a reverse transcriptase–independent, noncanonical
function [72,73] that remains to be clarified (Figure W6).
In summary, depending on the preexisting pathway of telomere
maintenance, both telomerase inhibition and the introduction of
telomerase activity are permissive for clonal evolution in neoplasia.
This allows increased genome plasticity by the generation of novel
structural chromosome anomalies and also through polyploidization.
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Figure W1. p53-related polyploidization in the MIN HCT-116 cell line: Dilution cloning of p53 null HCT-116 cells led to the selection of
cultured populations composed solely of tetraploid cells with 86 to 90 chromosomes (DAPI, 630×) (A). In the absence of telomere
dysfunction, the rates of endogenous mitotic and interphase WGDs are significantly elevated in the p53 null HCT-116, as compared
to p53-proficient parental cells (B). Statistics by paired t test or chi-square test.
Table W1. Literature Indicating Mutational Status of p53 in a Panel of Human Cancer and
Immortalized Cell Lines.
Cell Line p53 Status* Reference
HeLa WT [1]
SW-480 M [2]
MCF-7 WT [3]
HCT-15 WT [3]
T-24 M [4]
A-549 WT [3,5]
HCT-116 WT [3]
U2-OS WT [6]
Saos2 M [7]
VA-13 M [8]
HIO-118 M [9]
GM-847 M [10]
LS-2 WT [11]
LISA-2 WT [11]
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Figure W2. Silencing of hTERT at SW-480 cells. RT-PCR shows that expression levels of hTERT are reduced by 30% to 40%when SW-480
are transiently transfected with siTERT and 50% to 60% when transduced with lentivirus carrying shRNA for TERT.
Figure W3. Expression of hTERT/hTERC and TRAP assays: Semiquantitative RT-PCR assays for hTERT and hTERC in VA-13 derivative cell
lines (A). TRAP assays in the same panel of cell lines (B).
Figure W4. Telomerase inhibition in the VA-13TA (+hTERC+hTERT) cells increases the rates of telomere dysfunction–driven poly-
ploidization: Telomerase inhibition through MST312 is accompanied by a significant increase in the frequencies of mitotic WGD that
generates hyperpolyploid nuclei composed from more than 200 chromosomes (n = 100 nuclei; DAPI, 630×). Statistics by paired t test
or chi-square test.
Figure W5. Frequencies of clustered amplified centrosomes and multinucleated cells after inducible telomerase activity: Quantification
of immunofluorescence assays using antibodies specific for α- and γ-tubulins and DAPI staining shows that 5 days of inducible recon-
stitution of telomerase activity in VA-13InTAa, b, and c cells increase both rates of amplified centrosomes (more than two centrosome
foci) (A) and frequencies of clustered amplified centrosomes per cell (B). The evaluation of the percentages of binucleated or multinu-
cleated cells did not reveal significant differences before and after induction of telomerase activity (C). Immunofluorescent microscopy
examples of cells with one, two, or more (amplified) centrosomes (yellow or green foci, yellow arrows) and of multinucleated cells (red
arrows), in VA-13 cell lines (DAPI, blue; 630×) (D).
Table W2. Nomenclature and Description of VA-13 Cell Lines.
Full Name Abbreviation Inserts hTERC/hTERT Expression Telomerase Activity
Va-13 parental WT None −hTERC/−hTERT −
VA-13 +hTERC/+TERT TA pBabePurohTERT and pU1hTERC +hTERC/+TERT +
VA-13 + G7-189–KRAB EV TrePurohTERT, rtTAsM2, KRABG418 −hTERC/−hTERT −
VA-13 G7-189–KRAB + doxycycline InTERT TrePurohTERT, rtTAsM2, KRABG418 −hTERC/+hTERT −
VA-13 H2-9 InTAa TrePurohTERT, rtTAsM2, KRABG418, hTERCpssi6499 +hTERC/−hTERT −
VA-13 H2-9 + doxycycline InTAa + doxycycline TrePurohTERT, rtTAsM2, KRABG418, hTERCpssi6499 +hTERC/+TERT +
VA-13 H2-11 InTAb TrePurohTERT, rtTAsM2, KRABG418, hTERCpssi6499 +hTERC/−hTERT −
VA-13 H2-11 + doxycycline InTAb + doxycycline TrePurohTERT, rtTAsM2, KRABG418, hTERCpssi6499 +hTERC/+hTERT +
VA-13 G7-189–KRAB-V6499 InTAc TrePurohTERT, rtTAsM2, KRABG418, hTERCpssi6499 +hTERC/−hTERT −
VA-13 G7-189–KRAB-V6499 + doxycycline InTAc + doxycycline TrePurohTERT, rtTAsM2, KRABG418, hTERCpssi6499 +hTERC/+hTERT +
Figure W6. Opposing roles of telomerase activity and its major
components hTERT and hTERC, in the generation of polyploidy
during neoplastic cell growth: Simultaneous expression of hTERT
and hTERC, leading to RT-mediated telomere lengthening by telo-
merase activity, maintains low levels of polyploidy. Depletion of
hTERT or abrogation of telomerase activity accelerates WGD. In
this context, telomerase and p53 may act as independent sup-
pressors of WGD (A). The ALT pathway displays frequently dys-
functional telomeres and higher rates of WGD as compared to
cells using telomerase activity. Constitutive exogenous expression
of hTERC in ALT cells, which lack hTERC, suppresses the ALT
machinery of telomere elongation, transiently introducing elevated
rates of telomere dysfunction and WGD. These effects are highly
accelerated at the interface between the action of ALT machinery
and the activation of telomerase. However, constitutive expres-
sion of both hTERT and hTERC and long-term restoration of telo-
merase activity in ALT cells lead to ALT repression, genome
stabilization, and suppression of endogenous WGD. Moreover,
in ALT cells that lack hTERC and hTERT, ectopic expression of
hTERT alone suppresses WGD through unknown noncanonical
reverse transcriptase–unrelated functions (B).
